deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT02086604

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sponsor: Celgene

Conditions Lymphoma, Large B-Cell, Diffuse
Interventions Brentuximab vedotin Lenalidomide
Updated 16 times since 2017 Last updated: Feb 16, 2022 Started: Sep 18, 2014 Primary completion: Jun 9, 2017 Completion: Jan 12, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02086604, this PHASE1 trial focuses on Lymphoma, Large B-Cell, Diffuse and remains completed. Sponsored by Celgene, it has been updated 16 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Sep 2017 · 6 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jul 2019 · 12 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Sep 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 11 earlier versions

  1. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Apr 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  6. Jul 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1

  8. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. Mar 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  10. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene
  • Seagen Inc.
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations